BioStem Technologies, Inc. (BSEM)
OID · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About BioStem Technologies, Inc.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Quarterly Financials
| Metric | 2024-09-30 | 2024-12-31 | 2025-09-30 |
|---|---|---|---|
| Revenue | 18.4M | 102.9M | 10.5M |
| Gross Profit | 14.2M | 99.3M | 9.3M |
| Operating Income | 9.3M | 8.5M | 1.4M |
| Net Income | 6.8M | 15.5M | 761K |
| Diluted EPS | $0.32 | $nan | $0.03 |
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 4.3M | 6.9M | 16.7M | 301.8M |
| Gross Profit | 2.9M | 6.0M | 15.4M | 288.1M |
| Operating Income | -1.6M | -4.7M | -7.8M | 31.2M |
| Net Income | -1.4M | -7.2M | -8.5M | 31.9M |
| Diluted EPS | $-0.12 | $-0.63 | $-0.62 | $1.47 |